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Abstract
Achromobacter species are increasingly being detected in cystic fibrosis (CF) patients, where they can establish chronic infec-
tions by adapting to the lower airway environment. To better understand the mechanisms contributing to a successful coloniza-
tion by Achromobacter species, we sequenced the whole genome of 54 isolates from 26 patients with occasional and early/late 
chronic lung infection. We performed a phylogenetic analysis and compared virulence and resistance genes, genetic variants 
and mutations, and hypermutability mechanisms between chronic and occasional isolates. We identified five Achromobacter 
species as well as two non- affiliated genogroups (NGs). Among them were the frequently isolated Achromobacter xylosoxidans 
and four other species whose clinical importance is not yet clear: Achromobacter insuavis, Achromobacter dolens, Achromo-
bacter insolitus and Achromobacter aegrifaciens. While A. insuavis and A. dolens were isolated only from chronically infected 
patients and A. aegrifaciens only from occasionally infected patients, the other species were found in both groups. Most of 
the occasional isolates lacked functional genes involved in invasiveness, chemotaxis, type 3 secretion system and anaerobic 
growth, whereas the great majority (>60%) of chronic isolates had these genomic features. Interestingly, almost all (n=22/23) 
late chronic isolates lacked functional genes involved in lipopolysaccharide production. Regarding antibiotic resistance, we 
observed a species- specific distribution of bla
OXA
 genes, confirming what has been reported in the literature and additionally 
identifying bla
OXA-2
 in some A. insolitus isolates and observing no bla
OXA
 genes in A. aegrifaciens or NGs. No significant difference 
in resistance genes was found between chronic and occasional isolates. The results of the mutator genes analysis showed that 
no occasional isolate had hypermutator characteristics, while 60% of early chronic (<1 year from first colonization) and 78% of 
late chronic (>1 year from first colonization) isolates were classified as hypermutators. Although all A. dolens, A. insuavis and 
NG isolates presented two different mutS genes, these seem to have a complementary rather than compensatory function. In 
conclusion, our results show that Achromobacter species can exhibit different adaptive mechanisms and some of these mecha-
nisms might be more useful than others in establishing a chronic infection in CF patients, highlighting their importance for the 
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DATA SUMMARY
The authors confirm all supporting data, code and protocols 
have been provided within the article or through supplemen-
tary data files.
INTRODUCTION
Achromobacter species are ubiquitous Gram- negative bacilli, 
widely distributed in aquatic environments and soil, and 
increasingly found in nosocomial settings. They act as oppor-
tunistic pathogens in certain populations, such as subjects 
with cystic fibrosis (CF), where these microorganisms can 
survive for a long time in both lower and upper airways [1]. 
The genus Achromobacter comprises 22 named species and 
multiple genogroups [2]; whole genome sequencing data are 
available for all 22 species but complete reference genomes 
are available only for seven of them: Achromobacter deleyi, 
Achromobacter denitrificans, Achromobacter insolitus, Achro-
mobacter pestifer, Achromobacter ruhlandii, Achromobacter 
spanius and Achromobacter xylosoxidans. The type species 
A. xylosoxidans is the most often isolated Achromobacter 
species among CF patients and more than half of CF patients 
with airway colonization by A. xylosoxidans develop chronic 
infection, which has been associated with a decline in respira-
tory function and lung inflammation [1, 3–5]. Of note, an 
outbreak caused by another species, A. ruhlandii, was reported 
at two Danish CF centres [6, 7].
Lung infection caused by Achromobacter results either from 
acquisition from the environment or from direct/indirect 
transmission [7, 8] and is usually complicated by the innate 
and acquired multidrug resistance carried by these micro-
organisms. Approximately 50 drug- resistance- associated 
genes have been predicted in the A. xylosoxidans type strain 
[9, 10]. A. xylosoxidans is intrinsically resistant to aminogly-
cosides, many cephalosporins and aztreonam [9, 11] but only 
a few intrinsic resistance mechanisms have been identified 
to date. The resistance- nodulation- cell division (RND)- 
type multidrug efflux pump AxyAB- OprM is involved in 
resistance to cephalosporins (except cefepime), aztreonam, 
nalidixic acid, fluoroquinolones and chloramphenicol [12], 
while AxyXY- OprZ and AxyEF- OprN are responsible for 
resistance to aminoglycosides and levofloxacin, respectively 
[13, 14]. Moreover, the chromosomally encoded narrow- 
spectrum class D lactamase blaOXA-114 showed hydrolysis of 
piperacillin and ticarcillin [15]. In addition, clinical isolates 
of A. xylosoxidans may exhibit acquired resistance, especially 
for beta- lactams. To date, genes identified include IMP- type 
carbapenemase genes blaIMP-1, blaIMP-10 and blaIMP-19 [16, 17], 
VIM- type carbapenemase- encoding genes blaVIM-1 [18] and 
blaVIM-2 [19], the extended- spectrum beta- lactamase- encoding 
gene blaVEB-1 [20], and the metallo- lactamase- encoding gene 
blaTMB-1 [21].
With regard to pathogenic mechanisms, similar to other 
gram- negative pathogens, A. xylosoxidans expresses cell 
membrane- bound virulence factors such as the Vi capsular 
polysaccharide, involved in surface adhesion and protection 
from phagocytosis and toxins, and the O- antigen, which 
elicits a host immune response [22]. Lipopolysaccharide 
(LPS) also induces key inflammatory cytokines [23]. 
A. xylosoxidans is also equipped with various secretion 
systems that mediate the release of molecules to provide capa-
bility for invasion of the host cells, but little is known about 
its exoproducts [24, 25]. Previous Achromobacter compara-
tive genomics analyses showed that virulence genes related 
to the type 3 secretion system (T3SS) are more common in 
CF isolates than in environmental strains [22, 26]. Genome 
analysis also showed the presence of genes encoding colicin V, 
a protein cytotoxic to similar bacteria, and aepA, involved in 
cellulase and protease regulation [24]. In addition, production 
of phospholipase C and ability to inactivate the Pseudomonas 
aeruginosa quinolone signal molecule were observed [27, 28]. 
Moreover, a heat- stable cytotoxic factor, associated with an 
increase of pro- inflammatory cytokines in vitro, was identi-
fied [29]. Jakobsen and colleagues also investigated the pres-
ence of secreted virulence factors known to be important for 
other CF pathogens such as P. aeruginosa, but reported the 
absence of extracellular proteases, chitinase and rhamnolipids 
in clinical strains. More recently, we detected protease secre-
tion from A. xylosoxidans CF clinical isolates [30]. Regarding 
the biofilm mode- of- growth, A. xylosoxidans showed poor 
surface adhesion [24] but can form unattached or loosely 
attached aggregates, held together by polysaccharides forming 
Impact Statement
Achromobacter species can develop chronic lung infec-
tions in cystic fibrosis (CF) patients, which have been 
associated with worsening of the clinical condition. 
Although the frequency of infection by these opportun-
istic pathogens is increasing, little is still known about 
the mechanisms that are involved in their pathogenicity 
and persistence. To better elucidate these features, 
we analysed the genome of 54 isolates collected from 
both occasionally and chronically infected patients. This 
approach represents a novelty in the available literature, 
as the majority of studies have focused on chronic infec-
tion only, while the comparison with occasional isolates 
may allow us to identify genetic markers of persistence. 
Moreover, most of the available information regards the 
type species Achromobacter xylosoxidans, while data 
are lacking about other clinically relevant species. We 
identified four of them in our collection and addition-
ally performed species- specific analyses. Our results 
show the occurrence of different adaptive mechanisms 
in terms of virulence, antibiotic resistance, within- host 
genomic evolution and hypermutation, suggesting that 
some features might be more useful than others to estab-
lish chronic infections. These findings could support the 
creation of diversified treatment regimens and improve 
the management and clinical outcome of Achromobacter 
species lung infections in CF patients.
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a peripheral shell around the bacterial cells [31]. This ability 
might help bacteria to form complex communities and 
survive in a hostile environment such as CF lungs.
Another mechanism contributing to the persistence of patho-
gens in the airways of CF patients is the ability to genetically 
adapt during chronic infection through accumulation of 
pathoadaptive mutations [25]. This phenomenon can be 
accelerated due to mutations in the DNA mismatch repair 
system, giving rise to hypermutation events and to clonal 
diversification within the host [32]. The mutator genes whose 
mutations have been associated with development of hyper-
mutation are mutL, mutS, pfpI, superoxide dismutase, radA, 
radC, rad50, uvrA, uvrB, uvrC and uvrD [33].
To better understand the mechanisms underlying CF lung 
colonization by Achromobacter species, we sequenced the 
whole genome of 54 isolates from patients with both occa-
sional and chronic infection. By using different bioinformatics 
tools, we performed a phylogenetic analysis and compared 
virulence and resistance genes, genetic variants and muta-
tions, as well as hypermutability mechanisms between chronic 
and occasional Achromobacter isolates.
METHODS
Sample collection and identification
The samples analysed in this study have already been described 
in our previous work [34]. Briefly, 54 Achromobacter clinical 
isolates were collected from 53 sputum samples of 26 patients 
followed at the CF Centre of Verona (Italy) and were identi-
fied as Achromobacter species by MALDI- TOF- MS (bioMé-
rieux. Informed consent was obtained according to projects 
CRCFC- CEPPO026 and CRCFC- CEPPO031 approved by the 
local Ethical Committee. Collection was mainly performed 
in two time periods: 2014–15 and 2017–18. Sputum samples 
were collected approximately every 3 months for micro-
biological analysis. Only one isolate from each sample was 
included in the study, except for one P09 sample from which 
two morphologically different isolates were identified and 
included (9–4 and 9–5).
The classification of occasional and chronic infection was 
assessed using information regarding all Achromobacter 
isolates identified between 2013 and 2018. According to the 
European Consensus criteria (ECC), infection was defined 
as chronic when at least three positive cultures with at least a 
1 month interval between the samples were obtained within 
≥6 months from the first colonization event [35]. Isolates 
from chronically infected patients were further classified as 
early (<1 year from first colonization event) and late isolates 
(>1 year from first colonization). A minimum of one and a 
maximum of six successively collected isolates (mean=2.5 
isolates per patient) were recovered from chronically infected 
patients with a mean time delay of 197 days (range=21–1182 
days). Only one isolate was recovered from each occasion-
ally infected patient, except for P06 and P12 from which we 
recovered two isolates with a time delay of 112 and 155 days, 
respectively.
Genome sequencing
Collected isolates underwent whole genome sequencing 
at the Technological Platform Centre of the University of 
Verona as previously described [34]. Sequencing data were 
submitted to the NCBI SRA database with project number 
PRJEB40979. Genomic DNA was extracted using a QIAamp 
DNA Blood Mini Kit (Qiagen) and its quality was assessed 
using Nanodrop (Thermo Fisher Scientific) and Fragment 
Analyzer (Agilent Technologies). Libraries were prepared 
using the KAPA PCR- free kit and sequenced on a NextSeq500 
Illumina (Illumina) platform generating 150 bp paired- end 
reads with mean reads yield of 10978104 and mean coverage 
of 190×. Read quality controls, de novo assembly and genome 
annotation were performed similarly to our previous work 
[30]. Details on the sequencing and de novo assembly are 
available in Table S1 (available in the online version of this 
article).
Phylogenetic analysis
Based on MALDI- TOF identification results, all 
complete A. xylosoxidans genomes stored in the NCBI 
RefSeq database [36] (n=7 – January 2020, accessions: 
GCF_900475575.1, GCF_001051055.1, GCF_001558755.2, 
GCF_001558915.1, GCF_001559195.1, GCF_000165835.1 
and GCF_001457475.1) were considered as reference 
genomes for this study.
The average nucleotide identity (ANI) among all available 
Achromobacter species genomes, regardless of their assembly 
status (n=142 – NCBI RefSeq database, January 2020), and all 
sequenced isolates was calculated using FastANI [37] in order 
to ensure the correct species classification of the reference 
and isolate genomes. Isolates were considered to belong to 
the same species when ANI≥95 %, whereas isolates having 
ANI<95% with all available Achromobacter species genomes 
were considered as unaffiliated to any species sequenced up 
to now and referred to as non- affiliated genogroups (NGs) 
in this work [38]. This was further supported by in silico 
multilocus sequence typing (MLST) scheme analysis (Table 
S2). After ANI calculation, some reference genomes depos-
ited as A. xylosoxidans showed ANI>95% with genomes of 
other Achromobacter species (A. insuavis, A. aegrifaciens, 
A. dolens incomplete genome) suggesting their misclassifica-
tion. Thus, in this study they were used as reference genomes 
for isolates having ANI>95%, with the exception of A. dolens, 
whose complete reference genome was not available yet. In 
order to avoid using incomplete genomes as reference, the 
A. ruhlandii complete reference genome was used because 
it had the closest phylogenetic relationship with A. dolens. 
In addition, the A. insolitus reference genome (accession: 
GCF_008245125.1) was considered for the analysis, as it 
showed ANI>95% with some genomes.
The phylogenetic tree was generated performing a core 
genome alignment using the parsnp tool of the Harvest‐
OSX64‐v1.1.2 suite [39]. The tree file in newick format was 
used as input in Microreact [40] together with a metadata file 
for visualization.
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Functional annotation of relevant genomic 
variants
Analysis of variants was performed according to the Bacdist 
pipeline [41] considering all the genome sequences coming 
from the same patient and belonging to the same clone type 
(maximum SNP distance between clonally related isolates 
was 217) against the closest reference genome. Details on 
variant analysis results are available in Table S3. The amino 
acid sequences of genes presenting variants or mutations 
(here defined as variants that cause gene loss of function) 
were extracted and, using eggnog- mapper v1 [42], each 
gene product was classified in one of 25 eggnog functional 
categories, further grouped into four eggnog main categories: 
information storage and processing, cellular processes and 
signalling, metabolism, and poorly characterized.
Virulence factors and antibiotic resistance genes
In order to determine the presence of virulence factor and 
antibiotic resistance genes, the de novo assemblies were 
analysed using blast [43] against the PATRIC database 
(accessed January 2020) [44] and using Abricate [45] to search 
against the Resfinder database (accessed January 2020) [46]. 
Matches were filtered, thus considering matches with at least 
50% gene coverage and 95% gene identity.
The presence of mutations was evaluated in two ways. To 
analyse genes that are present in the reference genomes, the 
defence mechanism category of the eggnog- mapper output 
was taken into consideration: the presence of mutations was 
evaluated, and the functional impact of missense variants was 
predicted using the Provean protein tool. In order to analyse 
genes that are present in the isolates genomes but not in the 
reference, blast and Abricate outputs were considered: genes 
having an identity <100% were analysed by extracting the 
corresponding amino acid sequence and using blastp against 
the non- redundant (nr) database. The functional effect of 
each mutation was predicted using the Provean protein tool 
[47]. Heatmaps were generated for visualization purposes 
using the pheatmap R package v1.0.8 [48]. Fisher’s exact test 
was performed per clone type to ascertain the significance of 
results of statistical testing using R v3.5.
Mutator genes
The genetic basis of hypermutation was investigated from 
whole genome sequencing data by analysing genes involved 
in this phenomenon. The following list of mutator genes taken 
from the literature was considered: mutL, mutS, pfpI, super-
oxide dismutase, radA, radC, rad50, uvrA, uvrB, uvrC and 
uvrD [33]. In order to verify the presence of hypermutator 
strains, a combination of factors such as the occurrence of 
high- impact mutations and deleterious missense in mutator 
genes (Table S4), the transition/transversion rate and overall 
and per- site mean yearly variant rate (Table S3) were taken 
into consideration. Additional information on the classifica-
tion of the isolate is reported in Table S5.
RESULTS
Fifty- four Achromobacter clinical isolates were longitudinally 
collected over 5 years from the sputum samples of 26 patients 
followed at the CF Centre of Verona (Italy). Among them, 17 
presented chronic lung infection while nine were occasion-
ally colonized. Fig. 1 shows the sample collection timeline 
and the first colonization event for each patient (data avail-
able since 2013). In 10 patients with chronic infection (P01, 
P02, P05, P08, P09, P10, P13, P18, P19, P21) we collected 
isolates identified as early colonisers (<1 year from first 
colonization); the first isolate collected from four of them 
(P02, P09, P13, P21) coincides with the first colonization 
event. Moreover, we collected both early and late (>1 year 
from first colonization) colonizing strains from four chroni-
cally infected patients (P01, P05, P08, P10). In two of these 
patients (P01, P05) early and late isolates were isolated a few 
months apart (5 months between isolates 1–1 and 1–2; 2 
months between isolates 5–3 and 5–4). From two patients 
with occasional infection we collected Achromobacter species 
twice during the sampling periods (~3 months apart in P06, 
~5 months apart in P12).
Phylogenetic analysis
Fig. 2 shows the phylogenetic tree based on core genome 
alignment of 54 collected Achromobacter species isolates and 
seven reference genomes. In order to accurately classify the 
isolates in the genus Achromobacter, we calculated the ANI 
among all available Achromobacter species genomes and 
the genomes of our isolates. As a result of the phylogenetic 
analysis, five Achromobacter species were identified: A. aegri-
faciens, A. dolens, A. insolitus, A. insuavis and A. xylosoxidans. 
The majority of isolates was identified as A. xylosoxidans 
(67%, n=36), followed by A. insuavis (13%, n=7), A. dolens 
(7%, n=4), A. aegrifaciens (7%, n=4) and A. insolitus (6%, 
n=3). Among a total of 26 patients, 17 (65%) were infected by 
A. xylosoxidans, three (12%) by A. aegrifaciens, three (12%) by 
A. insolitus, two (8%) by A. insuavis and one (3%) by A. dolens. 
Interestingly, four strains [3] isolated from two patients (P03, 
P16) showed an ANI <95% against all the analysed genomes 
suggesting that they likely belong to Achromobacter species 
with no genomic assembly available yet. Because solely based 
on phylogenetic information, in this study we refer to them 
as non- affiliated genogroups (NGs).
A. xylosoxidans and A. insolitus were collected from both 
patients with chronic and occasional infections. By contrast, 
A. aegrifaciens was only observed in occasionally infected 
patients while A. insuavis, A. dolens and NG isolates estab-
lished chronic infections. For each of the patients with more 
than one isolate (10 with chronic and two with occasional 
infection) the genetic relatedness between genomes was 
also evaluated. As expected, all strains isolated from each 
chronic patient were clonally related (maximum SNP distance 
between clonally related isolates was 217). For the occasion-
ally infected patients with more than one isolate, one of them 
(P06) harboured clonal isolates while different clones were 
identified in the other one (P12).
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Virulence factors and antibiotic resistance
The results of the virulence factor analysis (Fig. 3) showed that 
argininosuccinate synthase, carbamoyl phosphate synthase 
large chain, hfq and large subunit ribosomal protein L36p 
are present in all collected isolates. These proteins are mainly 
involved in protein synthesis and stress response. The differ-
ences among early chronic infection isolates (n=20, <1 year 
from first colonization), late chronic infection isolates (n=23, 
>1 year from first colonization) and occasional infection 
isolates (n=11) were investigated. To evaluate differences 
in gene functionality, we took into account the presence of 
mutations in virulence factor genes (Table S6). All late chronic 
isolates (n=23/23) and 90% (n=18/20) of early chronic isolates 
carried functional genes associated with the ability to grow 
in an anaerobic environment (17 clonetypes, P=0.002), while 
only 45% (n=5/11, four clone types) of occasional isolates 
had this potential. Moreover, 96% (n=22/23) of late chronic 
isolates lacked genes involved in LPS production or carried 
mutations in these genes (10 clone types, P=0.036). Occasional 
isolates showed a significantly lower content of functional 
genes associated with the ability to infect cells (55%, n=6/11, 
five clone types, P=0.028) and, to a lesser extent, chemotactic 
movement (55%, n=6/11, five clone types, P=0.194) and T3SS 
(73%, n=8/11, seven clone types, P=0.11).
Focusing on differences among species, the results 
suggested that A. aegrifaciens (n=3), A. insolitus (n=3) and 
all the NG isolates (n=4) carried a restricted number of 
genes related to virulence. The analysis showed the absence 
of respiratory nitrate reductase (anaerobic growth), GDP 
mannose 4,6 dehydratase (pathogenicity) and liN (flagellar 
protein) genes in A. aegrifaciens, A. insolitus and one NG 
isolate. T3SS genes were also absent in these isolates and 
in one additional A. xylosoxidans occasional isolate. fliP 
and fliC genes (flagellar proteins) were not present in 
A. aegrifaciens or A. insolitus genomes together with the 
serum resistance- linked gene yihY, which was also absent 
in all NG isolates. Endotoxin- related genes were all found 
to be present in some A. xylosoxidans genomes while a 
putative oxidoreductase was also detected in all A. insuavis 
isolates (n=4). Moreover, UDP 2 acetamido 3 amino 2,3 
dideoxy d- glucuronic acid acetyltransferase gene (O antigen 
biosynthesis) was also found in A. dolens genomes (n=4). 
Finally, the putative cysteine hydrolase ycaC gene was found 
in A. aegrifaciens and in the majority (94%, n=34/36) of 
Fig. 1. Isolate collection timeline. Dates of collection of Achromobacter species isolates and first colonization event are shown for each 
patient enrolled in the study. A minimum of one isolate and a maximum of six isolates were collected from 26 patients between 2014 
and 2018. +=first colonization event; ㅁ=occasional isolates; ㅇ=early chronic isolates; ●=late chronic isolates; in some cases, isolates 
correspond with the first colonization event (superimposed symbols). In the left column, patient ID numbers are reported; coloured dots 
indicate the Achromobacter species of the isolates collected from each patient; a bicoloured dot indicates that isolates belonging to two 
species were recovered from the patient.
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A. xylosoxidans isolates, while motA (flagellar motility) was 
only present in A. aegrifaciens genomes.
Differences among chronic and occasional isolates were also 
investigated by species. In contrast to the chronic isolates, 
A. xylosoxidans occasional isolates (n=5/36) all carried fliP 
and NADP- dependent malic enzyme (growth in gluconeo-
genic conditions) genes while occasional isolates belonging 
to the NGs (n=1/4) lacked cheB, cheW, cheY (chemotaxis), 
fliN (flagellar protein), yscS (T3SS) and respiratory nitrate 
reductase. Conversely, no differences were detected among 
A. insolitus chronic and occasional isolates (n=3).
From the results of the antibiotic resistance genes (Fig. 4), 
the most represented genes are the sulfonamide resistance 
gene sul1 and the aac(6′) family aminoglycoside acetyl-
transferase, followed by class D β-lactamase blaOXA genes. 
The analysis showed a species- specific distribution of blaOXA 
genes: blaOXA-114 in A. xylosoxidans, blaOXA-243 in A. insuavis, 
blaOXA-364 in A. dolens, blaOXA-2 in A. insolitus (except for 
isolate 14–1 carrying no blaOXA genes), and no blaOXA genes 
in A. aegrifacies or NG isolates. Moreover, blaCARB-2 was 
found in isolates from patient P01. In addition to blaOXA 
genes, 31% of all isolates carried other antibiotic resistance 
genes. Among the isolates presenting deleterious variants 
– compromising gene function – in antibiotic resistance 
genes (Table S7), 54% (n=7/13) carried mutations in at least 
one bla gene.
Mutator genes
The genetic basis of hypermutation was investigated by 
verifying the occurrence of high- impact mutations and 
deleterious missense within genes involved in this phenom-
enon: mutL, mutS, pfpI, superoxide dismutase, radA, radC, 
rad50, uvrA, uvrB, uvrC and uvrD [33]. Moreover, a 
combination of factors such as the transition/transversion 
rate and overall and per- site mean yearly variant rate were 
taken into consideration. Similarly to other CF pathogens 
presenting hypermutation events during chronic infec-
tion, in this study no occasional isolates of Achromobacter 
species (n=11) showed hypermutator characteristics, while 
60% of early chronic isolates (n=12, 4/10 patients) and 78% 
of late chronic isolates (n=18, 8/11 patients) were classified 
as hypermutators. In particular, patients from whom we 
collected both early and late isolates (n=4) showed different 
hypermutation onset patterns: P01 and P05 presented 
hypermutant strains in early isolates, in P10 hypermuta-
tion developed in late isolates and P08 isolates showed no 
hypermutation- linked phenomena.
The results of the mutator genes analysis, reported in Fig. 5, 
showed that all A. dolens (n=4), A. insuavis (n=4) and NG 
isolates (n=3) presented two different mutS genes. Moreover, 
A. insolitus (n=3), A. dolens and NG isolates lacked radC 
while A. dolens and NG isolates also lacked a functional uvr 
system.
Fig. 2. Phylogenetic tree based on core genome SNPs of 54 collected Achromobacter species isolates and eight reference genomes. △ 
indicates occasional infection isolates, ㅇ indicates chronic infection isolates, while ☆ indicates a reference genome. The symbols are 
coloured according to the Achromobacter species identified with ANI analysis. Arrows indicate genomes with ANI<95 % against all the 
analysed reference genomes; in this case, symbols are coloured according to the closest Achromobacter species reference genome that 
was used for variant analysis. Genomic distance scales are reported at the bottom of the figure.
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DISCUSSION
Achromobacter species are opportunistic pathogens that 
can cause lung infections in CF patients. Although chronic 
colonization has been associated with a decline in respira-
tory function, increased frequency of exacerbations and 
lung inflammation, little is still known about its pathogenic 
mechanisms. To provide new insights about Achromobacter 
virulence, antibiotic resistance and evolution, we performed 
bioinformatics analysis of 54 whole genome sequences and 
compared these features between chronic and occasional 
isolates, as well as among different Achromobacter species. 
Although patients carrying these isolates were defined as 
chronically or occasionally infected based on their clinical 
microbiological history since 2013, clinical isolates included 
in this study were mainly collected in 2014–15 and 2017–18, 
thus limiting the continuous observation of adaptation during 
these 5 years. Nonetheless, they still provide longitudinal data 
that can support the understanding of pathogenicity and 
persistence, particularly in poorly characterized microorgan-
isms such as Achromobacter species. Moreover, we further 
compared isolates collected within the first year of chronic 
colonization (early chronic isolates) with those collected later 
(late chronic isolates) in order to observe early changes occur-
ring during the very first phase of chronic colonization, when 
eradication is still likely to be feasible, and identify markers of 
persistence that might be associated with an enhanced risk of 
eradication therapy failure.
As expected, the majority of isolates belong to A. xylosoxidans 
(65%) while none was identified as A. rhulandii, the second 
most frequently recovered species in the USA and Argentina 
and previously reported to be responsible for outbreaks in 
Danish CF centres [49–51]. We also identified four other 
species whose clinical importance is less clear: A. aegrifa-
ciens, A. dolens, A. insolitus and A. insuavis. The prevalence 
of A. dolens (3%) and A. insolitus (12%) in our patients was 
comparable with those reported in previous studies (2–17%) 
while dissimilarities were observed for A. aegrifaciens (12%) 
with respect to the literature (5%) [49, 50, 52–54]. Also, the 
prevalence of A. insuavis (8%) is similar to that described in 
Argentina (5%) but differs from Denmark (24%) [49, 50]. 
Interestingly, four isolates showed a low ANI (<95%) against 
all the available Achromobacter genomes, and thus we were 
unable to classify them within known species. This suggests 
that they might belong to Achromobacter species not yet 
sequenced or even to new species. In this study we consid-
ered them as non- affiliated genogroups. Predictably, all 
the longitudinal isolates from chronic patients belonged to 
the same Achromobacter species and were clonally related. 
Interestingly, the same situation also occurred in one of the 
occasionally infected patients (P06).
Fig. 3. Virulence factor genes identified in Achromobacter species isolates. The heatmap shows the presence and number of virulence 
factor genes on a grey scale. Additional information regarding the microorganism species, infection type and gene functional annotation 
(PATRIC categories) is presented in the annotation rows and column.
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Considering the species affecting chronic and occasional 
patients, A. insuavis and A. dolens were isolated only from 
chronically infected patients, A. aegrifaciens only from 
occasionally infected patients, while all the other species 
(A. xylosoxidans, A. insolitus and NGs) were found in both 
groups. For some species we only have a few isolates, and 
this may suggest that some Achromobacter species might be 
more likely to establish a chronic infection in CF patients. In 
particular, A. aegrifacens – found in two occasional patients 
– lacks various genes related to virulence: this could limit its 
ability to colonize CF lungs. Indeed, A. agrifaciens as well as 
the majority of occasional isolates showed a lack of functional 
genes related to the ability to infect cells, chemotactic move-
ment, T3SS and anaerobic growth, whereas the great majority 
of chronic isolates have these potentials. In particular, anaer-
obic growth ability confers to the cells the ability to locate 
deeper within the mucous layer or within biofilm structures 
or in more hypoxic regions of the lung, where antibiotics can 
be dramatically less effective due to anaerobic conditions 
[55]. This can favour resistance of bacterial cells to antibiotic 
therapies and attack from neutrophils. Additionally, almost 
all (n=22/23) late chronic isolates lacked functional genes 
involved in LPS production, probably leading to a reduced 
recognition by the host defence system. For example, a 
reduction in the number of LPS lipid A acyl chains by other 
bacteria was shown to modulate the recognition of LPS by 
toll- like receptors [56]. These might represent evolutionary 
mechanisms that favour bacterial persistence.
Regarding antibiotic resistance, we observed a species- 
specific distribution of blaOXA genes. While the specificity of 
blaOXA-114, blaOXA-243 and blaOXA-364 respectively for A. xylosox-
idans, A. insuavis and A. dolens has already been reported 
in the literature [57], we observed no blaOXA genes in 
A. aegrifaciens, NGs or one A. insolitus isolate (out of three). 
Additionally, we identified blaOXA-2 in two A. insolitus isolates. 
However, we found that blaOXA-2 does not follow a species- 
specific distribution when analysing all the available genome 
assemblies belonging to this species (n=16). Among the 
isolates presenting deleterious variants in antibiotic resist-
ance genes (n=13), 54% carried mutations in at least one bla 
gene. These mutations have been bioinformatically predicted 
to compromise protein function, probably reverting an 
antibiotic- resistant phenotype to a sensitive one, potentially 
influencing the results of antibiotic profiling with implications 
for therapies.
No significant difference in resistance genes was found between 
chronic and occasional isolates. Besides blaOXA, the most well- 
represented antibiotic resistance genes among all isolates are 
the sulfonamide resistance gene sul1 and the aac(6′) family 
aminoglycoside acetyltransferase, both frequently found 
within mobile genetic elements such as integrons, plasmids 
Fig. 4. Antibiotic resistance genes identified in Achromobacter species isolates. The heatmap shows the presence of antibiotic resistance 
genes on a black and white scale. Additional information regarding the microorganism species and the infection type is presented in 
the annotation rows.
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and transposons carried by other Gram- negative opportun-
istic pathogens [58]. Moreover, all the isolates belonging to 
one chronically infected patient (P01) carried the blaCARB-2 
gene, usually found in P. aeruginosa, another microorganism 
frequently involved in CF lung infections. Interestingly, in 
this patient both blaCARB-2 and sul1 were found to be carried 
by an integron. Moreover, we previously observed that these 
isolates carry various P. aeruginosa insertion sequences [34], 
supporting the possibility of inter- species genetic transfer. 
Further analysis of Achromobacter resistance- related mobile 
genetic elements could provide additional insights into anti-
biotic resistance acquired through its interaction with other 
microorganisms.
Overall, we detected a small number of genes linked to 
antibiotic resistance while a previous study using a multiple- 
database- based annotation approach predicted up to 50 drug- 
resistance associated genes in the A. xylosoxidans type strain 
[9]. However, that study analysed only one genome, using 
an approach that is hardly applicable to a large number of 
genome sequences due to the intensive manual effort required. 
To overcome this limitation, we first evaluated and compared 
the content of multiple databases to select the one able to 
ensure the most comprehensive outcome achievable with a 
more standard single- database- based approach. Nonetheless, 
the available databases report a restricted number of robustly 
annotated genes, not specific for Achromobacter species, prob-
ably leading to an underestimation of their presence. This lack 
currently limits the possibility of performing a more accurate 
analysis of the antibiotic resistance genes on a large number 
of strains belonging to this specific genus and highlights the 
need of a more specific database.
Regarding bacterial evolution, we focused on the study of 
hypermutation – in which defects in DNA repair processes 
promote an increased mutation rate, one of the main mech-
anisms favouring bacterial persistence in CF airways. The 
occurrence of hypermutation during chronic colonization 
of the CF lung has been demonstrated for various micro-
organisms such as P. aeruginosa [32, 59–61], Burkholderia 
cepacia complex [62] and A. xylosoxidans [30, 63]. Simi-
larly, no occasional isolates showed hypermutator charac-
teristics while 60% of early chronic and 78% of late chronic 
isolates were classified as hypermutators. Interestingly, the 
results of analysis of the mutator genes showed that all 
A. dolens, A. insuavis and NG isolates presented two 
different mutS genes (mismatch repair). To our knowledge, 
this peculiarity has not previously been reported. To validate 
this finding, we analysed mutS genes present in the avail-
able reference genomes of A. dolens (n=6) and A. insuavis 
(n=3): while the former presented two copies of the gene, in 
A. insuavis its copy number (one or two) was variable among 
the assemblies. One could hypothesize that the presence 
of an additional mutS could decrease the hypermutability 
potential. However, we identified hypermutator isolates 
carrying mutations in a single mutS gene, thus suggesting 
that both genes are needed for effective mismatch repair 
and indicating that they have a complementary rather 
Fig. 5. Mutator genes identified in Achromobacter species isolates. Heatmap (a) shows the presence and number of mutator genes on a 
grey scale. Heatmap (b) shows the presence and type of mutations in these genes on a grey scale. Additional information regarding the 
microorganism species and the infection type is presented in the annotation rows. *Hypermutable isolates.
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than compensatory function. Further studies are needed 
to elucidate the role of mutS genes in these species, their 
involvement in hypermutability and their importance for 
pathogenicity.
The presence of hypermutators in the bacterial popula-
tions of the CF airways is often associated with the parallel 
occurrence of different subpopulations with different 
phenotypic traits [32]. The study of subpopulations requires 
the isolation of more colonies – preferably, morphologically 
different – from the same sample. In this study, we were 
able to identify morphologically different clones only in 
one sample (isolates 9–4 and 9–5), while a single isolate 
was collected from each of all the other samples. However, 
we cannot exclude that morphologically similar clones were 
present in the collected samples. Since the design of the 
isolate collection limited our ability to investigate Achromo-
bacter subpopulations in CF airways, the variations that we 
observed over time within longitudinal isolates may reflect 
longitudinal evolution as well as intra- patient diversity. The 
most accurate approach to study intra- patient bacterial 
adaptation would be to analyse successively recovered clon-
ally related isolates coming from the same patient against 
the first isolate recovered from that patient. However, due 
to a technological limit in the sequencing strategy (short- 
read technology) a complete genome of the first isolates 
could not be obtained. Thus, analysis of the isolates here was 
performed using a same- patient same- clone type approach; 
that is, we analysed all the isolates coming from the same 
patient and having the same clone type using the closest 
reference genome. In particular, for the majority of identi-
fied species the reference was a complete reference genome 
of the same species, while for A. dolens and NG isolates 
the reference was the closest complete reference genome 
available, since no complete reference genomes are avail-
able yet (e.g. A. dolens isolates were analysed against the 
A. ruhlandii reference genome).
In conclusion, the variety of virulence and antibiotic 
resistance genetic profiles observed in the different species 
underlines the importance of accurate species identification 
to properly manage the infection and apply diverse thera-
peutic regimens. Lung colonization not only by A. xylosox-
idans but also by other species has already revealed clinically 
relevant consequences such as a high risk of pulmonary 
exacerbation [51] or high transmissibility among patients 
[6, 7]. Our results support that Achromobacter species can 
exhibit different adaptive mechanisms and suggest that 
some of them might be more useful to establish a chronic 
infection in CF patients, highlighting their importance for 
the clinical setting and the need for further studies of the 
less clinically characterized Achromobacter species.
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